Updated:
Sino Biopharmaceutical Limited
Theresa Tse chairs HKEX-listed Sino Biopharmaceutical, a Hong Kong–headquartered healthcare group that runs one of China's largest domestic pharma...
Sino Biopharmaceutical Limited
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
Hong Kong
City
Hong Kong
Corporate office
Hong Kong, Hong Kong
Additional offices
New York, NY, United States
Principals
Tse, Theresa Y Y (谢其润)
董事会主席
Cheng, Tania (郑翔玲)
董事会副主席
Tse, Eric S Y (谢承润)
首席执行官
Sector focus
Frequently asked questions
Who runs investment and strategic decisions at Sino Biopharmaceutical?
The board chair, Theresa Tse (谢其润), alongside vice chair Tania Cheng (郑翔玲) and CEO Eric Tse (谢承润), form the top executive layer. The firm's public listing on the Hong Kong Stock Exchange means investment allocation and pipeline prioritization are subject to board governance and Hong Kong–listed-company rules, not an unconstrained family-investment-committee structure.
Is Sino Biopharmaceutical a family office or an operating company?
It functions as a hybrid. The Tse family controls the entity through board-level roles, but the vehicle is a publicly traded pharmaceutical corporation (1177.HK), not a private investment office. This means family wealth is interwoven with public-market capital, and decisions are disclosed under Hong Kong continuous-obligation rules rather than private family-office reporting.
What therapeutic areas does the firm focus on?
The disclosed pipeline and product portfolio concentrate on oncology, liver disease, respiratory therapies, and surgical/analgesic treatments. The firm segments its innovation effort into these four disease areas, visible in its public product-center disclosures.
Does the firm allocate to external fund managers or direct deals?
The model is almost entirely direct operating control of subsidiary pharmaceutical businesses and internal R&D programs. There is no public evidence of a fund-of-funds program, SPV-based co-investments, or club-deal activity alongside external GPs. The capital vehicle is the operating company itself, not a discretionary allocator.
How is the firm connected to the broader Tse family wealth?
The exact wealth-origin narrative is not publicly detailed, but family members hold the chair, vice chair, and CEO positions, indicating that the listed company serves as the central instrument for the family's healthcare holdings. No separate private investment office or foundation is disclosed on the corporate site.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: